



GAU 1645  
#6  
RECEIVED  
MAR 15 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Quingping Jiang et al.  
Application No. : 09/626,566  
Filed : July 27, 2000  
For : NOVEL CHEMILUMINESCENT SUBSTRATES OF HYDROLYTIC  
ENZYMES AND THEIR USE IN ASSAYS  
Examiner : (Not Assigned)  
Attorney's Docket : CCDLT-300XX

TECH CENTER 1600/2900

Group Art Unit: 1645

\*\*\*\*\*  
I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Assistant Commissioner for Patents, Washington,  
D.C. 20231 on 3/12/01.

By: Arthur S. Morgenstern  
Arthur S. Morgenstern  
Registration No. 28,244  
Attorney for Applicants

\*\*\*\*\*

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

It is desired to cite for the record in this application the  
enclosed references listed on the attached copy of PTO Form #1449. The  
paragraph(s) marked below are applicable to this Information Disclosure  
Statement.

- [ ] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached  
Information Disclosure Statement is being filed within three  
months of the filing date of the above identified national  
application or within three months of the date of entry of the  
national stage as set forth in 37 C.F.R. § 1.491 of the above  
identified application. Accordingly, applicant(s) believes that  
no fee or statement under 37 C.F.R. § 1.97(e) is required.

- ☐ (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- ☐ (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- ☐ (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
- ☐ a statement under 37 CFR § 1.97(e); or
- ☐ the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

- ☐ (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(i).

STATEMENT UNDER 37 C.F.R. § 1.97(e) (1)

- ☒ (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Art was cited in PCT International Search Report mailed 2/1/2001, in International Application No. PCT/US00/20429 filed 7/27/2000.

STATEMENT UNDER 37 C.F.R. § 1.97(e) (2)

- ☐ (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a

counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.


If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

QINGPING JIANG ET AL.

By:



Arthur S. Morgenstern  
Registration No. 28,244  
Attorney for Applicants

WEINGARTEN, SCHURGIN,  
GAGNEBIN & HAYES LLP  
Ten Post Office Square  
Boston, Massachusetts 02109

Telephone: (617) 542-2290  
Telecopier: (617) 451-0313

ASM/jds  
Enclosure  
245378

<b>Form PTO-1449</b> <b>(REV. 8-83)</b>				<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>		ATTY. DOCKET NO. CCDLT-300XX		APPLICATION NO. 09/626,566	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>						<div style="font-size: 2em; font-weight: bold;">RECEIVED</div> <div style="font-weight: bold;">MAR 15 2001</div>		APPLICANT: Qingping Jiang et al.	
								<div style="font-weight: bold; font-size: 1.2em;">TECH CENTER 1600/2900</div>	
				FILING DATE July 27, 2000		GROUP 1645			

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*
		4,810,636	3/7/89	Corey	435	14	
		5,656,426	8/12/97	Law et al.	435	6	

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)	
	Renault, Jean, et al., "Hétérocycles à fonction quinone. I. Acridinediones-1,4 à action antitumorale potentielle"; Eur. Jour. of Medicinal Chemistry - Chimica Therapeutica, vol. 16, no. 1, Jan.-Feb., 1981-16, pp. 24-34.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.